Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
14 participants
OBSERVATIONAL
2018-04-01
2025-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Noninvasive Imaging of Heart Failure: A Pilot Study
NCT01160471
Validation of CMR Against Invasive Haemodynamics in Patients With HFpEF
NCT03251183
Rapid Diagnosis of Myocardial Damage and Coronary Stenosis With Magnetic Resonance Imaging (MRI)
NCT00188123
Heart Failure With Preserved Ejection Fraction and Its Cardiac MR Characteristics of Different Subtypes
NCT06916611
Cardiac Fibroblast Activation Detected by 68Ga-FAPI PET/MR
NCT04723953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must be able to read and understand English
* Participants must sign the informed consent form
* Elevated and delayed peak creatine kinase-MB and troponin I (cTnI) and troponin T (cTnT) in blood serum,
* ST elevation detected on ECG
Exclusion Criteria
* advanced renal disease (estimated glomerular filtration rate 30 mL/min) or hypersensitivity to gadolinium
* presence of a cardiac pacemaker or implanted cardiac cardioverter defibrillator
* pregnancy
* personal or family history of hypertrophic cardiomyopathy
* inability to provide informed consent
* history of seizure disorder
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
827697
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.